ImmuPharma currently has five lead compounds in development, each representing a potentially significant breakthrough in its field.

www.lupuzor.com Lupuzor™, for the treatment of Lupus, has received the highly accredited 'Gold Standard' approval by the US FDA for its Phase III trial with a Special Protocol Assessment and Fast Track designation. Lupuzor™, has now commenced its pivotal Phase III trial.


ImmuPharma is publicly listed in London, trading under the symbol IMM, or IMM:LN on Bloomberg.


Our cancer treatment drug in development acts by preventing angiogenesis and proliferation.
WELCOME to ImmuPharma

ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial. Further details on the trial can be seen at ClinicalTrials.gov ImmuPharma is led by a commercially focused Board and management team with extensive industry experience.

Share Price

Market Cap